Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-12-01T09:08:35.207Z Has data issue: false hasContentIssue false
  • English
  • Français

Dopaminergic imaging: clinical utility now and in the future

Published online by Cambridge University Press:  15 August 2011

Zuzana Walker  and
Joanne Rodda
Zuzana Walker*
Affiliation:
University College London and North Essex Partnership NHS Foundation Trust, Mental Health Unit, St Margaret's Hospital, Epping, Essex, UK
Joanne Rodda
Affiliation:
Research Department of Mental Health Sciences, University College London, London, UK
*
Correspondence should be addressed to: Zuzana Walker, MD, FRCPsych, University College London and North Essex Partnership NHS Foundation Trust, Mental Health Unit, St Margaret's Hospital, The Plain, Epping, Essex, CM16 6TN, UK. Phone: +44 1279-827-893; Fax: +44 1992-571-089. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Over the past ten years, dopaminergic imaging has become increasingly part of the assessment and diagnosis of dementia. There are numerous PET and SPECT ligands available that target different steps in the process of neurotransmission. Abnormalities in dopaminergic imaging measures are consistent features of dementia with Lewy bodies (DLB) and other parkinsonian syndromes, and can be used to facilitate diagnosis, particularly in distinguishing between DLB and Alzheimer's disease. This review summarizes present knowledge in this area and the implications for current and future clinical practice.

Keywords

dopaminergic imagingdementia with Lewy bodiesparkinsonian syndromes[123I] FP-CIT-SPECT[18F]DOPA- PET[11C]DTBZ- PET
Type
Review Article
Information
International Psychogeriatrics , Volume 23 , Supplement S2: Clinical use of neuroimaging in dementia: an international perspective , September 2011 , pp. S32 - S40
Copyright
Copyright © International Psychogeriatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. and Kragh-Sorensen, P. (2003). Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Archives of Neurology, 60, 387–392.Google Scholar
Antonini, A. et al. (2003). 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurological Science, 24, 149–150.Google Scholar
Ballard, C. et al. (2006). Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology, 67, 1931–1934.Google Scholar
Braak, H., Del, T. K., Rub, U., de Vos, R. A., Jansen Steur, E. N. and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24, 197–211.Google Scholar
Burn, D. J., Sawle, G. V. and Brooks, D. J. (1994). Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. Journal of Neurology, Neurosurgery & Psychiatry, 57, 278–284.Google Scholar
Ceravolo, R. et al. (2003). Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. Neurological Science, 24, 162–163.Google Scholar
Ceravolo, R. et al. (2004). Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. Journal of Neural Transmision, 111, 1065–1073.Google Scholar
El Fakhri, G. et al. (2006). Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. European Journal of Nuclear Medicine and Molecular Imaging, 33, 87–92.Google Scholar
Gilman, S. et al. (2004). Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Annals of Neurology, 55, 774–780.CrossRefGoogle ScholarPubMed
Hort, J. et al. (2010). EFNS guidelines for the diagnosis and management of Alzheimer's disease. European Journal of Neurology, 17, 1236–1248.Google Scholar
Hu, X. S. et al. (2000). 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology, 55, 1575–1577.Google Scholar
Kemppainen, N. et al. (2003). Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. European Journal of Neuroscience, 18, 149–154.Google Scholar
Klaffke, S. et al. (2006). Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Movement Disorders, 21, 1724–1727.Google Scholar
Koeppe, R. A., Gilman, S., Junck, L., Wernette, K. and Frey, K. A. (2008). Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimer's Dementia, 4, S67–S76.Google Scholar
Laureys, S. et al. (1999). Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. Journal of Neurology, 246, 1151–1158.CrossRefGoogle ScholarPubMed
Lopez, O. L. et al. (2002). Research evaluation and prospective diagnosis of dementia with Lewy bodies. Archives of Neurology, 59, 43–46.Google Scholar
McKeith, I. G. et al. (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 65, 1863–1872.CrossRefGoogle ScholarPubMed
McKeith, I. et al. (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, 6, 305–313.Google Scholar
Merdes, A. R. et al. (2003). Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology, 60, 1586–1590.Google Scholar
National Institute for Health and Clinical Excellence (2006). National Clinical Guidance Number 42. NICE-SCIE Clinical Guideline on supporting people with dementia and their carers in health and social care. http://www.nice.org.uk/CG42Google Scholar
Nelson, P. T. et al. (2010). Low sensitivity in clinical diagnoses of dementia with Lewy bodies. Journal of Neurology, 257, 359–366.CrossRefGoogle ScholarPubMed
O'Brien, J. T. et al. (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology, 61, 919–925.CrossRefGoogle ScholarPubMed
O'Brien, J. T. et al. (2009). Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. British Journal of Psychiatry, 194, 34–39.CrossRefGoogle ScholarPubMed
Pasquier, F., Lebert, F., Lavenu, I. and Guillaume, B. (1999). The clinical picture of frontotemporal dementia: diagnosis and follow-up. Dementia & Geriatric Cognitive Disorders, 10 Suppl 1, 10–14.Google Scholar
Piggott, M. A. et al. (1999). Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain, 122 (Pt 8), 1449–1468.CrossRefGoogle ScholarPubMed
Piguet, O., Hornberger, M., Mioshi, E. and Hodges, J. R. (2011). Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurology, 10, 162–172.Google Scholar
Pizzolato, G. et al. (1996). Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology, 47, 1065–1068.Google Scholar
Plotkin, M. et al. (2005). Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. Journal of Neural Transmission, 112, 677–692.Google Scholar
Raffel, D. M. et al. (2006). PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. Journal of Nuclear Medicine, 47, 1769–1777.Google Scholar
Rinne, J. O., Laine, M., Kaasinen, V., Norvasuo-Heila, M. K., Nagren, K. and Helenius, H. (2002). Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology, 58, 1489–1493.CrossRefGoogle ScholarPubMed
Sedaghat, F. et al. (2007). Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography. Neurodegenerative Diseases, 4, 382–385.Google Scholar
Suzuki, M., Desmond, T. J., Albin, R. L. and Frey, K. A. (2002). Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Annals of Neurology, 51, 767–771.CrossRefGoogle ScholarPubMed
Van Laere, K. et al. (2006). Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. Journal of Nuclear Medicine, 47, 384–392.Google Scholar
Vlaar, A. M. et al. (2008). Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. European Neurology, 59, 258–266.Google Scholar
Walker, R. W. and Walker, Z. (2009). Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Movement Disorders, 24 Suppl 2, S754–S759.Google Scholar
Walker, Z., Costa, D. C., Janssen, A. G., Walker, R. W., Livingstone, G. and Katona, C. L. (1997). Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. European Journal of Nuclear Medicine, 24, 609–614.Google Scholar
Walker, Z. et al. (2002). Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. Journal of Neurology, Neurosurgery & Psychiatry, 73, 134–140.Google Scholar
Walker, Z. et al. (2007). Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. Journal of Neurology Neurosurgery & Psychiatry, 78, 1176–1181.Google Scholar
Zaccai, J., Brayne, C., McKeith, I., Matthews, F. and Ince, P. G. (2008). Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology, 70, 1042–1048.CrossRefGoogle Scholar